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Audience Response Question 
40 yo male with NIDM and Class III heart failure.  
Creatinine 1.0 and K 4.1.  LVEF 30%.  HR 90/min 
Lisinopril 5 mg qd and Toprol XL 150 mg qd. 
 
Next step should be: 
a) Add aldactone 25 mg qd 
b) Add digoxin 0.125 mg qd  
c) Refer for CRT-D 
d) Increase Lisinopril to 10 mg qd 
e) Add corlanor 
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Audience Response Question 
40 yo white male with NIDM and Class III heart 
failure.  Creatinine 1.0 and K 4.1.  LVEF 30%.  HR 
90/min.  QRS duration 170 msec.  Lisinopril 40 mg 
qd, Toprol XL 150 mg qd, aldactone 25 mg qd. 
 
Next step should be: 
a) Refer for CRT-D 
b) Add hydralazine/nitrates 
c) Add corlanor (ivabradine) 
d) Add entresto (sacubitril/valsartan) 
e) Change to Lisinopril to entresto 
(sacubitril/valsartan) 
Epidemiology of Heart Failure 
• Approximately 5.7 million Americans have CHF 
• 670,000 new cases annually 
• Five-year mortality rate as high as 50% 
• Most frequent cause of hospitalization in patients 
older than 65 years 
• Prevalence: 11.7% of population > 85 years old 
• DRG 127 (Congestive Heart Failure): 
• Primary Dx   990,000 hospitalizations/yr 
• Secondary Dx   2,000,000 hospitalizations/yr 
• Single largest expense for Medicare 
AHA. 2011 Heart and Stroke Statistical Update 
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Diastolic Dysfunction 
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Left Ventricular Dysfunction 
• Systolic:  Impaired contractility/ejection 
– Approximately two-thirds of heart failure 
patients have systolic dysfunction1 
• Diastolic:  Impaired filling/relaxation 
 Lilly, L.  Pathophysiology of Heart Disease.  Second Edition p 200 

Relative Doses of ACEI 
• Captopril   50 mg TID 
• Enalapril   20 mg BID 
• Lisinopril   40 mg qd 
• Ramipril   10 mg qd 
Target dose 
Blockade of RAAS 
Angiotensin I 
Angiotensinogen 
(Liver) 
AT1 AT2 
ACE 
Inhibitor 
ARB 
AT1 receptor blocker 
Bradykinin 
Inactive 
peptides Angiotensin II 
Vasodilation 
and cough 
CHARM-Alternative: ACEI intolerant Patients  
Primary outcome CV death or CHF hospitalisation 
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Candesartan 
% 
HR 0.77 (95% CI 0.67-0.89), p=0.0004 
Adjusted HR 0.70, p<0.0001 
Number at risk 
Candesartan  1013 929 831 434 122 
Placebo  1015 887 798 427 126 
3.5 
406 (40.0%) 
334 (33.0%) 
RRR=23% 
Granger CB et al.  Lancet  2003; 362:  772-776. 
Patients receiving diuretics, ACE inhibitors, ± digoxin; follow-up 6 months; placebo (n=84), carvedilol (n=261). 
*Multicenter Oral Carvedilol Heart Failure Assessment. 
†Mortality was not a planned end point in this study. 
‡P.05 vs placebo. 
§P=.07 vs placebo. 
P.001 vs placebo.  
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Placebo 25 mg bid 6.25 mg bid 12.5 mg bid Placebo 25 mg bid 6.25 mg bid 12.5 mg bid 
**P.005 vs placebo. 
§P.0001 vs placebo. 
Adapted from Bristow M et al. Circulation. 1996; 94: 2807–2816. 
Target Doses of Beta Blockers 
• Carvedilol 25 mg BID 
• Metoprolol Succinate 150 mg qd 
• Coreg CR 80 mg qd 
Inclusion Criteria 
NYHA Class 3 or 4 
LVEF < 35% 
Cr < 2.5 
K < 5.0 
Pitt B et al. NEJM 1999; 341: 709–717. 
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Randomized Aldactone 
Evaluation Study (RALES) 
RR 27% lower 
EMPHASIS-HF:  Eplerenone in NYHA II 
 
Zannad F et al. NEJM 2010. 
Hyperkalemia Secondary to 
Spironolactone for Heart Failure 
Juurlink D et al.  NEJM  2004; 351: 543-551. 
Admission Rate 
For Hyperkalemia 
Mortality from 
Hyperkalemia 
AHeFT: Overall Survival 
Taylor, A. et al. N Engl J Med 2004;351:2049-2057 
• NYHA III and IV 
• Full medical 
therapy 
• AA only 
PARADIGM-HF:  Sacubitril/Valsartan 
McMurray JJV et al. N Engl J Med 2014;371:993-1004 
McMurray JJV et al. N Engl J Med 2014;371:993-1004 
PARADIGM-HF:  Sacubitril/Valsartan 
Ivabradine:  CV death or HF 
Hospitalization 
Swedberg K, et al. Lancet. 2010;376(9744):875-885 
Ivabradine:  Hospitalization for HF 
Swedberg K, et al. Lancet. 2010;376(9744):875-885 
Ivabradine:  CV death 
Swedberg K, et al. Lancet. 2010;376(9744):875-885 
Achieving Cardiac Resynchronization 
 
Mechanical Goal: Atrially-synchronized  
biventricular pacing 
Right Atrial 
Lead 
Right Ventricular 
Lead 
Left Ventricular 
Lead 
CRT Improves Submaximal Exercise 
Distance Walked in 6 Minutes 
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P=0.004 
P=0.003 
P=0.005 
Baseline (meters) 
291 ± 101 
305 ± 85 
 Abraham W et al. NEJM 2002;346:1845-1853. 
CRT 
Control 
Patient Activity Improved Over 
Time in Patients with CRT  
Daily Physical Activity Measured by the InSync III
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• 56 InSync III patients monitored minutes of daily patient activity  
• 7-day means were compared from 1st week after implant at 2 weeks, 1 
month, and 3 months. 
 
 
Linde C, et al. Euro Heart J 2003; 24(Suppl); 30.  
†P = 0.012 
*P < 0.001 
*week 2 compared to  
week 1 
 †3 months Compared 
to 1 month  
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69 ± 10 
70 ± 10 
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) 
7.2 ± 4.9 
7.6 ± 6.4 
Baseline (%) 
22 ± 6 
22 ± 6 
Paired median change from baseline at 6 months.  Error bars are 95% CI. 
 Abraham W et al. NEJM 2002;346:1845-1853. 
CRT Improves Cardiac Function and Structure 
Indications for the Cardiac 
Resynchronization-ICD System 
 A CRT-ICD system is indicated for the reduction of 
HF symptoms in patients that meet the following 
criteria: 
– Moderate to severe heart failure (NYHA Class II-
IV) 
– QRS  120 msec (although substantially greater 
efficacy if > 150 msec) 
– LV ejection fraction  35% 
– Symptomatic despite  
maximized medical therapy 
CRT for  
NYHA Class IV  
Heart Failure 
2 Year Mortality with CRT/CRT-D in 
NYHA Class IV Patients 
Lindenfeld J et al.  Circulation 2007; 115: 204-212. 
COMPANION NYHA Class IV Patients 
Lindenfeld J et al.  Circulation 2007; 115: 204-212. 
RAFT:  CRT-D in NYHA Class II 
Tang A et al.  NEJM 2010. 
HEART TRANSPLANTS 
Kaplan-Meier Survival 
(Transplants: January 1982 - June 2010) 
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Half-life = 10 years
Conditional half-life = 13 years
N = 96,273 
J Heart Lung Transplant.  2012 Oct; 31(10): 1045-1095 
Heart Transplantation Volume 
Lund L. et al.  J Heart Lung Transpl 2015; 33: 996-1008. 
Mechanical 
Circulatory 
Support 
HeartMate II Improvements in BTT Survival 
from Clinical Trial to Commercial Use 
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Trial (N=486)
76% 
85% 
John, Naka, Smedira et al Ann Thor Surgery 2011 
MCS Prior to Cardiac Transplantation 
JHLT in press, 2016 
ENDURANCE Trial:  DT Survival 
Presented by Pagani F. et al.  ISHLT 2015, Nice, France 
 Bristow MR et al.  NEJM 2004; 350: 2140 – 2150. 
HeartMate III:  Full MagLev™ Technology  
Key Design Features: Large and Consistent Gaps 
– HeartMate III secondary flow paths are ~0.5 mm along the side, and ~1.0 mm pump above and 
below the rotor. 
– Conversely, hydrodynamic bearings are typically operated with much smaller gaps, 0.05 of 
a millimeter or so. 
– HeartMate III pump surfaces are flat and flow is undisturbed, wedging surfaces and other 
features required for hydrodynamic bearings are not required. 
~ 0.5 mm 
along the side 
~ 1.0 mm 
top and 
bottom 
Gap Size # of Red Blood Cells 
Full MagLev 1,000μm 167 
Hydrodynamic Bearing 50μm 8 
6-8 μm 
Stacked 
RBCs 
Note: The use of a red blood cell as a measuring unit is for illustration 
purposes and is not meant to imply actual blood flow quantities during 
operation. 
Comparison of Blood Flow Pathway Sizes 
U s i n g  a  R e d  B l o o d  C e l l  f o r  S c a l e  
40 
Artificial Pulse Overview 
• The HM III with full magnetic levitation and wide gaps is intrinsically capable of very sharp 
speed changes, enabling an “artificial pulse” feature that has so far in pre-clinical studies 
proved to contribute negligible hemolysis and require low incremental power 
consumption. 
• While unproven, augmenting the pulsatility that is generally diminished in rotary pump 
patients may have benefit for some patients or in certain circumstances, perhaps in part 
addressing adverse events such as; aortic insufficiency, bleeding and thrombogenesis 
FS = Fixed Speed (set by clinician) 
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time [s] 
rotor speed [rpm] 
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Conclusions 
• ACEI/ARB/beta blocker doses should be maximized 
• Aldosterone receptor antagonist for symptomatic patients 
• Hydralazine/nitrates for symptomatic African Americans 
• Consider Entresto (Sacubitril/Valsartan) as an alternative 
to ACEI/ARB in symptomatic LV systolic dysfunction 
• Consider Corlanor (Ivabradine) in symptomatic patients 
with elevated HR 
• CRT-D in patients who remain symptomatic, particularly 
NYHA Class II and III, and have prolonged QRS duration 
• CRT of questionable benefit in NYHA Class IV patients 
• MCS improves quality of life and functional capacity with a 
trade off of adverse events 
 
 
